Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.
Actively Recruiting
Researchers are evaluating the combination of Torvutatug samrotecan and bevacizumab compared with bevacizumab alone as a first-line maintenance treatment in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are Homologous Recombination Deficient HRD negative. The study focuses on patients whose cancer has not progressed after completing first-line platinum-based chemotherapy and bevacizumab. Participants must have confirmed HRD-negative status and folate receptor alpha status. Participants will be randomly assigned to receive either Torvutatug samrotecan together with bevacizumab or bevacizumab alone. Both treatments are given intravenously. Eligible patients must have completed at least 6 cycles of platinum-based chemotherapy and at least 3 cycles of bevacizumab in combination with chemotherapy. The study is open-label and planned to last several years, with treatment continuing as maintenance therapy following initial chemotherapy. During the study, participants will have regular assessments including monitoring for cancer progression, survival, time to additional therapies, and quality of life. Researchers will also monitor the safety and side effects of the treatments. The main measurement is progression-free survival, tracked for up to approximately 5 years. Overall survival and other outcomes will be followed for up to approximately 7 years. Participants health and adverse events will be regularly evaluated throughout the study period.